tbuckley/cabot-search huggingface dataset:
Reduced expression of cell cycle regulator p18INK4C in human hepatocellular carcinoma
Authors: Asahiro Morishita, Tsutomu Masaki, Hitoshi Yoshiji, Seiji Nakai, Tomohiro Ogi, Yoshiaki Miyauchi, Shuhei Yoshida, Toshiharu Funaki, Naohito Uchida, Yuko Kita, Fumi Funakoshi, Hisashi Usuki, Setsuo Okada, Kunihiko Izuishi, Seishiro Watanabe, Kazutaka Kurokohchi, Shigeki Kuriyama
Journal: Hepatology (2004)

Cyclins, cyclin-dependent kinases (Cdks), and Cdk inhibitors (CdkIs) are frequently altered in human cancer. p18 INK4C , a member of the INK4 family of CdkIs, is a potential tumor-suppressor gene product. However, the expression of p18 INK4C in hepatocellular carcinoma (HCC) remains unknown. The aim of this study was to examine the expression of p18 INK4C in various liver diseases including HCC and to assess its clinical significance in HCC. To that end, we examined the expression of p18 INK4C by immunohistochemistry in various liver diseases, including 51 HCCs, and also studied the relationship between p18 INK4C expression, the phosphorylation of retinoblastoma protein (pRb), and the activity level of Cdk4 and Cdk6. Immunohistochemical analysis revealed the frequent loss of p18 INK4C expression in HCC, especially in poorly differentiated HCC. The loss of p18 INK4C expression was shown to be associated with a poor prognosis compared with that associated with p18 INK4C - positivity. Further, the kinase activity of Cdk4 was found to be higher in p18 INK4C -negative HCCs than in p18 INK4C - positive HCCs. However, the level of Cdk6 activity was similar in the 2 groups of HCCs. In p18 INK4C - positive HCCs, p18 INK4C dominantly interacted with Cdk4 rather than with Cdk6. pRb phosphorylated at serine(Ser) 780 was detected more frequently in p18 INK4C - negative than in p18 INK4C - positive HCCs. In conclusion , the loss of p18 INK4C expression may play a role in the differentiation and development of HCC through the up-regulation of Cdk4 activity. (Hepatology 2004;40:677-686.)
What future for the regions?
Authors: C. Ham
Journal: BMJ (1992)

research.Moreover, many of the questions require progress in research methodology before the research itself can start.None of this, however, will change anything much unless there is the political will to grasp the nettles of central government policy that affect health.The greatest potential of the white paper is that it could force the government's hand.The white paper is an unparalleled chance to make the NHS reforms work in the interests of the people's health.As health professionals we should seize this opportunity.
Angiotensin converting enzyme inhibitors and diuretics.
Authors: B Cook
Journal: BMJ (1987)

years of age and sometimes younger, in addition to those aged over 75 years who are mentioned in the discussion papers.The diagnostic range includes the whole range of psychiatric morbidity, not only the demented.3Here is a hot spot of new and worthwhile activity, the very essence of the flexible responsive approach health services require.Performance indicators that cannot identify or monitor its dimensions will lead to the withdrawal ofresources and the activity will cease.
Randomised controlled trial of nurse practitioner versus general practitioner care for patients requesting "same day" consultations in primary care
Authors: P. Kinnersley
Journal: BMJ (2000)

<h3>Abstract</h3> <b>Objective:</b> To ascertain any differences between care from nurse practitioners and that from general practitioners for patients seeking "same day" consultations in primary care. <b>Design:</b> Randomised controlled trial with patients allocated by one of two randomisation schemes (by day or within day). <b>Setting:</b> 10 general practices in south Wales and south west England. <b>Subjects:</b> 1368 patients requesting same day consultations. <b>Main outcome measures:</b> Patient satisfaction, resolution of symptoms and concerns, care provided (prescriptions, investigations, referrals, recall, and length of consultation), information provided to patients, and patients9 intentions for seeking care in the future. <b>Results:</b> Generally patients consulting nurse practitioners were significantly more satisfied with their care, although for adults this difference was not observed in all practices. For children, the mean difference between general and nurse practitioner in percentage satisfaction score was −4.8 (95% confidence interval −6.8 to −2.8), and for adults the differences ranged from −8.8 (−13.6 to −3.9) to 3.8 (−3.3 to 10.8) across the practices. Resolution of symptoms and concerns did not differ between the two groups (odds ratio 1.2 (95% confidence interval 0.8 to 1.8) for symptoms and 1.03 (0.8 to 1.4) for concerns). The number of prescriptions issued, investigations ordered, referrals to secondary care, and reattendances were similar between the two groups. However, patients managed by nurse practitioners reported receiving significantly more information about their illnesses and, in all but one practice, their consultations were significantly longer. <b>Conclusion:</b> This study supports the wider acceptance of the role of nurse practitioners in providing care to patients requesting same day consultations.
1112. The Treatment with Intra Muscular (IM) Vascular Endothelial Growth Factor (VEGF) Gene Compared with Placebo for Patients with Diabetes Mellitus and Critical Limb Ischemia (CLI), a Double Blind Phase III Study
Authors: Yoka H. Kusumanto, Vincent Weel, Nanno H. Mulder, Andries J. Smit, Jan J. Dungen, Anneke M. Hooymans, Wim J. Sluiter, Rene A. Tio, Paul H. Quax, Rijk O. Gans, Robin P. Dullaart, Geke A. Hospers
Journal: Molecular Therapy (2005)

Background: Despite advances in revascularisation techniques, limb salvage and relief of ischaemic pain cannot be achieved in many patients with diffuse peripheral disease. This is especially true in diabetic patients where occlusions show a predilection for distal vessels. Earlier findings suggest that IM delivery of a plasmid encoding VEGF can promote the development of blood vessels in ischaemic limbs. Our objective was to determine the effect of IM administration of phVEGF165 (VEGF gene containing plasmid; 2 mg on day 1 and 28) on CLI, compared to placebo (0.9 % NaCl).
Higher levels of adiponectin in American than in Japanese men despite obesity
Authors: Takashi Kadowaki, Akira Sekikawa, Tomonori Okamura, Tomoko Takamiya, Atsunori Kashiwagi, Wahid R. Zaky, Hiroshi Maegawa, Aiman El-Saed, Yasuyuki Nakamura, Rhobert W. Evans, Daniel Edmundowicz, Yoshikuni Kita, Lewis H. Kuller, Hirotsugu Ueshima
Journal: Metabolism (2006)
Effect of Posture on Serum Lipids
Authors: Meng H. Tan, Errol G. Wilmshurst, Ray E. Gleason, J. Stuart Soeldner
Journal: New England Journal of Medicine (1973)

IT has been known for many years that postural changes affect the plasma volume and the concentration of certain blood constituents.1 2 3 4 5 6 In healthy subjects, the plasma volume decreases whereas the concentrations of certain nonfiltrable blood constituents increase on change from the recumbent to the upright position, and these alterations are reversed on reversal if the postural positions. Little account has been taken of such effects in clinical work. The importance of such changes became apparent during a study of the serum lipid responses during glucose tolerance tests in which numerous sequential samples were taken. This report describes the rapidity, magnitude . . .
Abstract 919: The influence of haplotype of interleukin-10 gene on the susceptibility and clinical outcome of non-Hodgkin lymphoma
Authors: Hyeon-Seok Eom, Mi Hwa Han, Sohee Park, Weon-Seo Park, Tak Yun, Hyun-Ju Kim, Kong Sun-Young
Journal: Cancer Research (2010)

Abstract Background: Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine, and single-nucleotide polymorphisms (SNP) of this gene have been reported to affect transcription and production of IL-10. Although the association between SNP and Non-Hodgkin lymphoma (NHL) and increased serum IL-10 levels in NHL patients than controls have been known, there were a few reports in context of haplotypes of whole IL-10 gene. In this study, we investigated the association between haplotype of IL-10 gene and the risk of NHL. Moreover, we investigated the association between IL-10 haplotype, and the overall survival and prognostic factors. Methods: A total of 209 NHL patients and 418 sex- and age- matched controls was included in this study. Through database searching 4 tagging SNPs covering 2.6 kb of IL-10 gene (rs3021094, rs1554286, rs1800872, and rs1800896) were selected considering ethnicity. Analysis was done using TaqMan probe or sequencing. Haplotype and linkage disequilibrium (LD) was analyzed by PHASE and Haploview program. We compared each genotype or haplotype frequency in controls with that in patients. Genotype was tested for its association with overall survival, clinical characteristics (e.g., cell lineage) and international prognostic indices including age, performance, LDH, stage and extra-nodal involvement. Results: All studied SNP were in Hardy-Weinburg equation in controls. There is no strong LD between four SNPs with r2 ranged from 0.002 to 0.211. Among 15 haplotypes identified by PHASE analysis, haplotype 1 (Ht1, TATT at rs3021094, rs1554286, rs1800872, and rs1800896) composed with all of dominant polymorphisms showed a significantly increased risk for developing NHL with odds ratios (OR) of 2.08 [95% confidence interval (CI); 1.47-2.96] and 5.17 [95% CI; 2.45-10.93] in single or both allele carrier of Ht1 than other haplotypes. There was no significant association between the haplotype of IL-10 and risk factors of NHL. Furthermore, Ht1 was shown to be associated with a significantly worse overall survival in patients with diffuse large B cell lymphoma (DLBCL) with CHOP (cyclophosphamide, adriamycin, vincristine and prednisone, n=37) chemotherapy done before introduction of rituximab therapy (p=0.04), while not significant in patients treated by R-CHOP (Rituximab plus CHOP, n=86) chemotherapy (p=0.27). Conclusions: This study showed that the IL-10 haplotype is a susceptibility marker for the development of NHL, and it was a significant prognostic indicator for DLBCL patients treated with CHOP. However, IL-10 haplotype was not a risk factor in DLBCL patients treated with R-CHOP. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 919.
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
Authors: E Tenedini, I Bernardis, V Artusi, L Artuso, E Roncaglia, P Guglielmelli, L Pieri, C Bogani, F Biamonte, G Rotunno, C Mannarelli, E Bianchi, A Pancrazzi, T Fanelli, G Malagoli Tagliazucchi, S Ferrari, R Manfredini, A M Vannucchi, E Tagliafico
Journal: Leukemia (2013)

With the intent of dissecting the molecular complexity of Philadelphia-negative myeloproliferative neoplasms (MPN), we designed a target enrichment panel to explore, using next-generation sequencing (NGS), the mutational status of an extensive list of 2000 cancer-associated genes and microRNAs. The genomic DNA of granulocytes and in vitro-expanded CD3+T-lymphocytes, as a germline control, was target-enriched and sequenced in a learning cohort of 20 MPN patients using Roche 454 technology. We identified 141 genuine somatic mutations, most of which were not previously described. To test the frequency of the identified variants, a larger validation cohort of 189 MPN patients was additionally screened for these mutations using Ion Torrent AmpliSeq NGS. Excluding the genes already described in MPN, for 8 genes (SCRIB, MIR662, BARD1, TCF12, FAT4, DAP3, POLG and NRAS), we demonstrated a mutation frequency between 3 and 8%. We also found that mutations at codon 12 of NRAS (NRASG12V and NRASG12D) were significantly associated, for primary myelofibrosis (PMF), with highest dynamic international prognostic scoring system (DIPSS)-plus score categories. This association was then confirmed in 66 additional PMF patients composing a final dataset of 168 PMF showing a NRAS mutation frequency of 4.7%, which was associated with a worse outcome, as defined by the DIPSS plus score.
F-18 Fluorodeoxyglucose PET in the Diagnosis of Vascular Invasion in Renal Cell Carcinoma
Authors: SHARON F. HAIN, JONATHAN GLEADLE, MICHAEL N. MAISEY
Journal: Clinical Nuclear Medicine (1999)

Renal cell carcinoma is well known to invade along the vena cava, eventually reaching the right atrium. It is equally well known that patients with carcinoma of any type have a high incidence of thromboembolism. When a thrombus is detected in the vena cava in patients with renal cell carcinoma, it is important for possible therapy to determine if the clot is thrombotic or contains tumor. The authors present a case of renal cell carcinoma with inferior vena caval thrombus for which PET scanning helped to show that the thrombus contained metastatic disease. FIGURE 1Fig. 1: An inferior vena caval thrombosis was identified in a 44-year-old man with a 2-year history of renal cell carcinoma with no known metastases. Initial investigations showed no other evidence of disease. Before further treatment was undertaken, a PET scan was performed to determine if the thrombosis contained only blood clot or tumor. The whole-body PET scan showed increased uptake in the inferior vena cava at the level of the renal vein consistent with metastatic renal cell carcinoma (a).FIGURE 2Fig. 2: A localized view of the abdomen shows the tumor (c) in relation to the right kidney (b). Given the result of the PET scan, the patient underwent exploratory laparotomy that confirmed tumor within the IVC. FDG PET has been shown to differentiate cardiac sarcomatous tumor from thrombus in the right ventricle (1). MRI has been shown previously to help differentiate thrombus from tumor in renal cell carcinoma (2). However, false-positive results have been reported (3). There are no reports of the use of PET in this situation.
Grandpa's Grandpa
Authors: Walter C. Bornemeier
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE SUCCESSFUL TREATMENT OF SNAKE BITE.
Authors: J. G. TUTEN
Journal: JAMA (1897)

June 1, 1896. M. O., aged 26 years, was bitten by a rattlesnake inside of gastrocnemius muscle of right leg four hours before we saw him. We found the patient suffering a great deal of pain and leg very much swollen; pulse rate 130 and very weak; respiration 48 and very much labored. The leg was very well corded in two places, one below and one above knee. I immediately made an incision two inches long at the place where the fangs entered, then a cross incision two inches long and then a circular incision, taking in the whole of the skin and muscle an inch all around where the fangs entered; then I poured in about two drachms of crude carbolic acid and about two drachms of permanganate of potash in crystals. I then gave him, hypodermically, one grain of permanganate of potash every hour for thirty-six hours and
Dipeptidyl Peptidase I as a Serum Marker of Allergic Reactions to Food
Authors: H.S. Whitworth, X.Y. Zhou, L. Lau, K. Bodey, M. Erlewyn-Lajeunesse, F. Millinchamp, J. Pedersen, J.S. Lucas, A.F. Walls
Journal: Journal of Allergy and Clinical Immunology (2011)
Effect of "fast track" admission for acute myocardial infarction on delay to thrombolysis.
Authors: A. C. Pell, H. C. Miller, C. E. Robertson, K. A. Fox
Journal: BMJ (1992)

OBJECTIVE--To evaluate the impact of a fast track triage system for patients with acute myocardial infarction. DESIGN--Comparison of delays in admission to hospital and in receiving thrombolytic treatment before and after introducing fast track system with delays recorded in 1987-8. Patients fulfilling clinical and electrocardiographic criteria for myocardial infarction were selected for rapid access to the cardiac care team, bypassing evaluation by the medical registrar. SETTING--Major accident and emergency, cardiac and trauma centre. SUBJECTS--359 patients admitted to the cardiac care unit during 1 February to 31 July 1990 with suspected acute infarction. MAIN OUTCOME MEASURES--Accuracy of diagnosis and delay from arrival at hospital to thrombolytic treatment. RESULTS--248 of the 359 patients had myocardial infarction confirmed, of whom 127 received thrombolytic treatment. The fast track system correctly identified 79 out of 127 (62%) patients who subsequently required thrombolytic treatment. 95% (79/83) of patients treated with thrombolysis after fast track admission had the diagnosis confirmed by electrocardiography and enzyme analysis. The median delay from hospital admission to thrombolytic treatment fell from 93 minutes in 1987-8 to 49 minutes in fast track patients (p less than 0.001). Delay in admission to the cardiac care unit was reduced by 47% for fast tract patients (median 60 minutes in 1987-8 v 32 minutes in 1990, p less than 0.001) and by 25% for all patients (60 minutes v 45 minutes, p less than 0.001). CONCLUSION--This fast track system requires no additional staff or equipment, and it halves inhospital delay to thrombolytic treatment without affecting the accuracy of diagnosis among patients requiring thrombolysis.
Disinfection of the Skin with Detergent Preparations of Irgasan DP 300 and Other Antiseptics
Authors: H. A. Lilly, E. J. L. Lowbury
Journal: BMJ (1974)

An evaluation of the relative effectiveness of 2% hexachlorophane and 0·75% Irgasan DP 300 bar soaps in disinfection of the hands showed that the former caused a significantly larger reduction in natural skin bacteria than the latter after one handwash and after six handwashings, three on each of two successive days. Repeated use of Irgasan DP 300 bar soap caused a significantly greater reduction in skin flora than repeated handwashings with unmedicated bar soap, but a single handwash gave no significant reduction in skin flora compared with a single use of the unmedicated soap. In a comparison of a 4% chlorhexidine detergent solution a 3% hexachlorophane detergent cream and a 2% Irgasan DP 300 detergent solution the 4% chlorhexidine detergent gave the largest mean reduction in skin bacteria after one handwash and after six handwashings and 2% Irgasan DP 300 a poor and erratic reduction after a single handwash. After six handwashings all three preparations gave large reductions in skin bacteria. The 2% Irgasan preparation showed some residual activity on the skin after handwashing though less than that with chlorhexidine and with hexachlorophane-chlorocresol detergent preparations.
Laparoscopic Findings in Polyarteritis Nodosa
Authors: J.A. Solis-Herruzo, T. Muñoz-Yagüe, Colina Ruizdelgado
Journal: Endoscopy (1981)

We describe the laparoscopic findings of 6 patients with histologically proven P.A.N. In 5 cases a fibrous thickening of the liver capsule was observed. The capsular thickening was present only along the course of the arteries, and with a segmental distribution, presented the appearance of an "arterial coat'. Biopsy of these segments demonstrated typical inflammatory infiltrates of P.A.N. None of the 248 laparoscopic examinations used as controls had such findings. In conclusion, these laparoscopic findings may represent the segmental arterial lesions of P.A.N., although further studies are necessary to establish its diagnostic sensitivity and specificity.
Abstract B62: miR-124 systemically enhances antitumor clearance by inhibiting STAT3 signaling and reversing glioma-associated immune suppression.
Authors: Jun Wei, Ling-Yuan Kong, Fei Wang, Shuo Xu, Tiffany Doucette, Sherise D. Ferguson, Yuhui Yang, Kayla McEnery, Krishan Jethwa, Olsi Gjyshi, Wei Qiao, Frederick Lang, Ganesh Rao, Greg N. Fuller, George A. Calin, Amy B. Heimberger
Journal: Cancer Research (2013)

Abstract MicroRNAs (miRs) have been shown to modulate critical gene transcripts involved in tumorigenesis, but their role in tumor-mediated immune suppression is largely unknown. In this study, we evaluated miRNAs that are preferentially down-regulated in glioblastoma and that interact with immune suppressive pathways as potential new therapeutics. On the basis of miRNA-gene expression libraries of glioblastoma, tissue microarrays, and molecular modeling, we selected miR-124 as the lead candidate for modulating signal transducer and activator of transcription 3 (STAT3) signaling, a key pathway mediating immune suppression of the tumor microenvironment. Upon up regulating miR-124 in glioma cancer stem cells (gCSCs), the STAT3 pathway was inhibited and the miR-124 reversed gCSC-mediated immune suppression of T cell proliferation and Th1 polarization and decreased gCSC-induced Foxp3+ regulatory T cells (Tregs). Treatment of immune-suppressed glioblastoma patient T cells with miR-124 induced marked effector response including up regulation of IL-2, IFN-γ and TNF-α. Both systemic administration of miR-124 or adoptive miR-124 transfected T cell transfers exerted potent anti-glioma therapeutic effects in clonotypic and genetically engineered murine models of glioblastoma and enhanced effector responses in the local tumor microenvironment. These therapeutic effects were ablated in nude murine systems. Our findings highlight the potential application of miR-124 as a novel immunotherapeutic agent for neoplasm treatment by exploiting the immune system to mediate direct tumor cytotoxicity. Citation Format: Jun Wei, Ling-Yuan Kong, Fei Wang, Shuo Xu, Tiffany Doucette, Sherise D. Ferguson, Yuhui Yang, Kayla McEnery, Krishan Jethwa, Olsi Gjyshi, Wei Qiao, Frederick Lang, Ganesh Rao, Greg N. Fuller, George A. Calin, Amy B. Heimberger. miR-124 systemically enhances antitumor clearance by inhibiting STAT3 signaling and reversing glioma-associated immune suppression. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B62.
Elevated Platelet-Associated IgG in Thrombotic Thrombocytopenic Purpura
Authors: John Morrison
Journal: JAMA (1977)

A 41-year--old woman with thrombotic thrombocytopenic purpura (TTP) was treated with prednisone and splenectomy with complete recovery from her illness. Analysis of the patient's platelets for immunoglobulins showed abnormally elevated levels in the range of those seen in thrombocytopenic patients with systemic lupus erythematosus, immune vasculitis, and infectious mononucleosis. This finding is consistent with the concept that the immune system may play a role in the pathogenesis of TTP.